International Stem Cell Corporation (ISCO) news stock charts
International Stem Cell Corporation (ISCO/ISCO.OB) Investment Summary:
International Stem Cell Corporation, a biotechnology company, focuses on the development of therapeutic and research products. The company is developing stem cells that are comparable in function to embryonic stem cells from which, cells for human transplant can be derived; techniques to cause those cells to be differentiated into the specific cell types required for transplant; and manufacturing protocols to produce these cells without contamination with animal by-products in compliance with the U.S. Food and Drug Administration requirements. Its cells could be used for the treatment of various diseases, including diabetes, liver disease, corneal disease, and retinal disease through cell tr...www.internationalstemcell.com
29 Employees
Founded in 2001
INTERNATIONAL STEM CELL CORP (ISCO:OTC Bulletin Board Market)
LAST $1.53 USD
CHANGE TODAY 0.00 0.00%
VOLUME 85.7K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of INTERNATIONAL STEM CELL CORP (ISCO)
|
OPEN
$1.54
|
PREVIOUS CLOSE
$1.53
|
|
|
DAY HIGH
$1.58
|
DAY LOW
$1.51
|
|
|
52 WEEK HIGH
02/2/10 - $1.98
|
52 WEEK LOW
05/7/09 - $0.40
|
|
|
MARKET CAP
82.5M
|
AVERAGE VOLUME 10 D
295.1K
|
|
|
EPS TTM
$-0.24
|
SHARES OUTSTANDING
53.9M
|
|
|
ISCO Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for INTERNATIONAL STEM CELL CORP (ISCO)
International Stem Cell Corporation Begins its Second Pre-Clinical Phase of Testing Retinal Pigment Epithelium Derived from Human Parthenogenetic Stem Cells for Treatment of Retinal Diseases
03/18/2010
International Stem Cell Corporation announced that its Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine, is starting a second phase of essential pre-clinical experiments to test retinal pigment epithelium derived from parthenogenetic stem cells. Follow on pre-clinical experiments will be conducted to rescue vision in disease models. Retinal pigment epithelium has been derived from parthenogenetic stem cells by the company's scientists in close collaboration with University of California, Irvine scientists. The retinal pigment epithelium cells will be tested for the presence of specific markers and for functional activity. Retinal pigment epithelium plays a critical role in maintaining proper eye function. Loss of function or dysfunction of retinal pigment epithelium is involved in a range of disabling eye conditions, particularly age-related macular degeneration that is the major cause of vision loss in seniors. Encouraging data from animal models have shown that visual degradation caused by age-related macular degeneration can be slowed through the transplantation of retinal pigment epithelium. One of the major barriers for this therapy is the lack of sufficient retinal pigment epithelium cells from suitable donated tissue.
International Stem Cell Corporation Announces Parthenogenetic Stem Cell Line Shown to Carry the Most Common Immune Genes Matched to the U.S. Population
03/2/2010
International Stem Cell Corporation announced that human parthenogenetic stem cell lines (hpSC), created by scientists from its Research and Therapeutic Development Group, have demonstrated ability to maintain the essential properties of immortal stem cells throughout extended laboratory cultivation. To date, ISCO has created 10 human parthenogenetic stem cell lines. One of these lines, named phSC-Hhom-4, has the most common set of HLA genes found in various U.S. population groups and may be useful to treat millions of people world-wide from a single cell line. After more than one hundred passages over more than two years of continuous in vitro cultivation, the line phSC-Hhom-4 has maintained pluripotent stem cell properties and continues to be used in experiments to create therapeutic derivatives targeted for treatment of liver, cornea, retina and neurodegenerative diseases. The differentiated derivatives of human parthenogenetic stem cells, obtained by ISCO scientists, promise to overcome the problem of immune-matching in tissue-replacement therapy. This is a significant differentiator from embryonic stem cells and a major reason why hpSC have the potential to become the first population-specific pluripotent stem cells available for use in the treatment of human diseases for different genders and racial groups across the world.
International Stem Cell Corporation Opens Facility for Development and Production of Clinical-Grade Stem Cell Products
02/5/2010
International Stem Cell Corporation announced that its new cell production facility has passed final building inspection, which will enable development and manufacturing of the company and its partners' clinical-grade stem cell products. ISCO has designed and built a unique cell manufacturing facility in Oceanside, California consisting of separate "suites" for development and production of different cell types from the company's proprietary human parthenogenic stem cell (hpSC) technology. The facility is located in close proximity to the fertility clinics that provide donated human eggs (oocytes) under ISCO's recently-established partnerships and also near leading Californian research institutions with whom ISCO collaborates on fundamental stem cell biology and therapeutic applications. ISCO will implement its parthenogenic stem cell processes at this facility during 2010 and adopt current good manufacturing practice (cGMP) standards. In parallel, ISCO will collaborate with world-leading scientists to demonstrate the therapeutic applicability and the potential immune-rejection advantages of hpSC lines relative to other stem cell classes.
International Stem Cell Corporation financial resources
ISCO Competitors
| Company | Last | Change |
| Aastrom Biosciences Inc | $1.72 USD | +0.05 |
| Advanced Cell Technology Inc | $0.10 USD | 0.00 |
| Biotime Inc | $6.65 USD | -0.04 |
| Cord Blood America Inc | $0.0089 USD | -0.0003 |
| Cryo-Cell International Inc | $1.44 USD | +0.14 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | ISCO | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 67.0x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 81.6x |
|
|
ISCO |
||
|
ISCO transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About International Stem Cell Corporation
International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment Epithelium (RPE) Derived from Human Parthenogenetic Stem Cells for Treatment of Retinal Diseases
2010-03-19 07:24:18
Quote: ISCONewswww.internationalstemcell.com,announced today that ISCO's Research and Therapeutic Development Group,together with a group of scientists from the University of California,Irvine (UCI), is starting a second phase of essential pre-clinicalexperiments to test retinal pigment epithelium derived fromparthenogenetic stem cells. Follow on pre-clinical experiments will beconducted to rescue vision in disease models.Retinal pigment epithelium (RPE) has been derived from parthenogeneticstem cells ...Read article
International Stem Cell Corporation Parthenogenetic Stem Cell Line Shown to Carry the Most Common Immune Genes Matched to the U.S. Population Retains Stem Cell Characteristics over Two Years in Culture, Which is Necessary for Therapeutic Va
2010-03-11 03:44:36
Quote: ISCONewswww.internationalstemcell.com,announced today that human parthenogenetic stem cell lines (“hpSCâ€),created by scientists from its Research and Therapeutic DevelopmentGroup, have demonstrated ability to maintain the essential properties ofimmortal stem cells throughout extended laboratory cultivation.To date, ISCO has created 10 human parthenogenetic stem cell lines. Oneof these lines, named phSC-Hhom-4, has the most common set of HLA genesfound in various U.S. population group...Read article
International Stem Cell Corporation Parthenogenetic Stem Cell Line Shown to Carry the Most Common Immune Genes Matched to the U.S. Population Retains Stem Cell Characteristics over Two Years in Culture, Which is Necessary for Therapeutic Va
2010-03-02 09:09:51
Quote: ISCONewswww.internationalstemcell.com,announced today that human parthenogenetic stem cell lines (“hpSCâ€),created by scientists from its Research and Therapeutic DevelopmentGroup, have demonstrated ability to maintain the essential properties ofimmortal stem cells throughout extended laboratory cultivation.To date, ISCO has created 10 human parthenogenetic stem cell lines. Oneof these lines, named phSC-Hhom-4, has the most common set of HLA genesfound in various U.S. population group...Read article
Skymark Research Initiates Independent Research Coverage on International Stem Cell Corporation
2010-03-01 08:37:59
Quote: 1, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on International Stem Cell Corporation (OTCBB: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial da...Read article
Biotech Stock Alert for International Stem Cell Corp. Issued by Beacon Equity
2010-03-01 08:37:58
Quote: The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.http://www.beaconequity.com/i/ISCOhttp://twitter.com/BeaconEquityInternational Stem Cell Corp. (ISCO) develops leading-edge stem cell technology called "parthenogenesis," a regenerative technology to reduce immune-rejection among many patients. The Company's parthenogenesis approach to combat medical pathologies utilizes unfertilized human eggs to ...Read article
International Stem Cell Corporation Opens Facility for Development and Production of Clinical-Grade Stem Cell Products
2010-03-01 08:37:58
Quote: ISCOwww.internationalstemcell.com,announced today that its new cell production facility has passed finalbuilding inspection, which will enable development and manufacturing ofthe company and its partners’ clinical-grade stem cell products.ISCO has designed and built a unique cell manufacturing facility inOceanside, California consisting of separate “suites†for developmentand production of different cell types from the company’s proprietaryhuman parthenogenic stem cell ...Read article
International Stem Cell Corporation Provides Strategic Update on the Company's Cornea Transplantation Program
2010-03-01 08:37:57
Quote: ISCOwww.intlstemcell.com,announced today that multiple international meetings taking placebetween ISCO’s executive management and researchers and clinicians fromcommercial entities in both Asia and Europe revealed significantclinical-commercial opportunities for the company’s stem cell-derivedhuman cornea technology in those regions.ISCO has discovered and filed for patents on a cell culture process forthe synthesis of fully human, cornea-like structures using either itsproprietary...Read article
Biotech Stock Alert for International Stem Cell Corp. Issued by Beacon Equity
2010-02-26 03:42:27
Quote: The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.http://www.beaconequity.com/i/ISCOhttp://twitter.com/BeaconEquityInternational Stem Cell Corp. (ISCO) develops leading-edge stem cell technology called "parthenogenesis," a regenerative technology to reduce immune-rejection among many patients. The Company's parthenogenesis approach to combat medical pathologies utilizes unfertilized human eggs to ...Read article
Skymark Research Initiates Independent Research Coverage on International Stem Cell Corporation
2010-02-25 02:33:25
Quote: 1, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on International Stem Cell Corporation (OTCBB: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial da...Read article
International Stem Cell Corporation Provides Strategic Update on the Company's Cornea Transplantation Program
2010-02-17 07:20:28
Quote: ISCOwww.intlstemcell.com,announced today that multiple international meetings taking placebetween ISCO’s executive management and researchers and clinicians fromcommercial entities in both Asia and Europe revealed significantclinical-commercial opportunities for the company’s stem cell-derivedhuman cornea technology in those regions.ISCO has discovered and filed for patents on a cell culture process forthe synthesis of fully human, cornea-like structures using either itsproprietary...Read article
Biotech Stock Alert for International Stem Cell Corp. Issued by Beacon Equity
2010-02-12 03:07:25
Quote: The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.http://www.beaconequity.com/i/ISCOhttp://twitter.com/BeaconEquityInternational Stem Cell Corp. (ISCO) develops leading-edge stem cell technology called "parthenogenesis," a regenerative technology to reduce immune-rejection among many patients. The Company's parthenogenesis approach to combat medical pathologies utilizes unfertilized human eggs ...Read article
International Stem Cell Corporation Opens Facility for Development and Production of Clinical-Grade Stem Cell Products
2010-02-05 02:05:15
Quote: ISCOwww.internationalstemcell.com,announced today that its new cell production facility has passed finalbuilding inspection, which will enable development and manufacturing ofthe company and its partners’ clinical-grade stem cell products.ISCO has designed and built a unique cell manufacturing facility inOceanside, California consisting of separate “suites†for developmentand production of different cell types from the company’s proprietaryhuman parthenogenic stem cell ...Read article
INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Unregistered Sale of Equity Securities
2010-02-05 02:05:15
Quote: The shares
of common stock issued in clause (iii) were sold in exchange for previously
issued securities in transactions exempt from registration pursuant to
Section 3(a)(9) of the Securities Act.
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
International Stem Cell Corporation
By:/s/ Ray WoodRay WoodChief Financial OfficerDated: February 3, 2010
......Read article
Skymark Research Initiates Independent Research Coverage on International Stem Cell Corporation
2010-02-02 02:20:05
Quote: 1, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on International Stem Cell Corporation (OTCBB: - ). Skymark Research is currently offering a complimentary trial subscription. To view our research go to:Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial da...Read article
International Stem Cell Corporation Announces Shareholder Conference Call
2010-02-01 02:58:02
Quote: Press ReleaseSource: International Stem Cell CorporationOn Thursday January 28, 2010, 7:30 am ESTOCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:),a California-based biotechnology company creating human stem cell linesfrom unfertilized eggs, today announced that it is has scheduled aconference call for February 5, 2010 at 10:00 a.m. PST. ISCO ChairmanMr. Kenneth Aldrich will discuss both the present status of the companyand its vision for the coming year. The dial-...Read article
International Stem Cell Corporation Announces Launch Strategy for Skin Care Product Line
2010-01-29 02:13:22
Quote: ISCOwww.internationalstemcell.com,announced today that it has retained the services of a highlyexperienced expert in the skin care industry, Raulee Marcus, to helpdesign a marketing program for its newly created line of skin careproducts based on ISCO’s proprietary Parthenogenic Stem Cells.Ms. Marcus has an extensive background in skin care products, havingbeen a key corporate executive with responsibilities for marketing, R&Dand sales at companies such as Neutrogena, Colgate-Palmolive an...Read article
International Stem Cell Corporation Announces Collaboration with Scripps Research Institute's Center for Regenerative Medicine to Study Parthenogenetic Stem Cells
2010-01-29 02:13:22
Quote: ISCOwww.internationalstemcell.comannounced today that it is collaborating with renowned stem cellresearcher Jeanne F. Loring, Ph.D., and the Scripps Research Institute(La Jolla, CA) to study parthenogenetic stem cells and potentiallytherapeutic cells that can be derived from them.ISCO has perfected a process for creating human stem cells fromunfertilized human eggs. These “parthenogenetic†stem cells have themedical advantage of allowing immune-matching to large segments of thepopula...Read article
International Stem Cell Corporation to Present at Multiple Near-Term Events
2010-01-29 02:13:21
Quote: ISCOwww.internationalstemcell.comABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):parthenogenesisparthenogenic, homozygous stem cell linewww.internationalstemcell.com.http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.FORWARD-LOOKING STATEMENTS:Statements pertaining to anticipated future financial and/oroperating results, future growth in research, technology, clinicaldevelopment and potential joint venture and other opportunities for thecompany and its subsidiary, along with other statements a...Read article
International Stem Cell Corporation's Chairman Discusses Creation of Cornea in a Petri Dish in December 11, 2009 Edition of Discovery News
2010-01-29 02:13:21
Quote: ISCOwww.intlstemcell.comDiscovery News.In the article, reporter Alyssa Danigelis writes about how, whilegrowing stem cells in the lab using blastocysts, researchers atInternational Stem Cell spotted something in the waste products usuallydiscarded from the petri dish that turned out to be a tiny translucentstructure of cells that resembled a human cornea.This little ball of cells, the article explained, might actually spareanimals from lab testing and be used for transplants in humans. Manycosme...Read article
International Stem Cell Corporation joins Information Portal StockProfile.com
2010-01-29 02:13:20
Quote: We're pleased to addStockProfile.com to our market awareness program and we will continue toexplore additional market outreach strategies.â€ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):parthenogenesisparthenogenic, homozygous stem cell linewww.internationalstemcell.comhttp://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.FORWARD-LOOKING STATEMENTS:Statements pertaining to anticipated future financial and/oroperating results, future growth in research, technology, clinicaldevelopment and p...Read article
Would you like to leave a comment about International Stem Cell Corporation ISCO/ISCO.OB
Find out what social network information about International Stem Cell Corporation are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides International Stem Cell Corporation's Stock there is more great penny stock and market information at Realpennies